Baylink Biosciences is focused on developing innovative antibody-drug conjugates (ADCs) for cancer treatment.

Dr. Alice Chen has over 25 years of experience in the biotech and pharmaceutical industry. She brings extensive experience in technology innovation, biologics and small molecule drug discovery, MOA research, as well as translational science expertise to Baylink. She held scientific and leadership roles at Novartis, NGM Biopharmaceuticals, 23andMe, and Asieris Pharmaceuticals where she contributed to the development of numerous drugs targeting oncology, metabolic disease, and autoimmune diseases. Prior to joining Baylink, she was SVP of Biology and Head of Translational Research at Asieris Pharmaceuticals. She received her Ph.D. in Neurosciences from Stanford University, and BS in Biology from Caltech.

Dr. David Yi is an accomplished immunologist with over 20 years of experience in basic and translational research, specialized in biologics drug development.

As a co-founder of Baylink, he plays a crucial role in fostering startup growth and strategic innovation.

His experience in biotech include leadership and scientific roles at NGM Biopharmaceuticals, AbbVie, 23andMe, and Staidson Biopharma, where he focused on biologics development for oncology and autoimmune indications.

Dr. Zhang joined Baylink in 2023, bringing over 30 years of experience in medicinal chemistry, with a deep specialization in linker design.

He had a long career at Nektar Therapeutics spanning two decades. Prior to joining Baylink, Wen was VP of Medicinal Chemistry at CSPC Dophen.

His extensive research has resulted in over 20 patents, and he has successfully advanced more than five drug candidates into clinical trials including 1 approved drug. Dr. Zhang held Ph.D. in Chemistry from Peking University in China.

An experienced clinical oncology biotech leader with broad experience in the full range of ADC discovery through clinical development at ImmunoGen and AbbVie. With successful programs in both heme and solid tumor oncology, he brings a wealth of knowledge to help support our pipeline of ADCs, providing evaluation of developing pipeline programs, strategic clinical and regulatory guidance, and investigator engagement to enable IND submission and expedient clinical trial execution.